Compare BioNTech SE - ADR (BNTX) vs Cipher Mining Inc (CIFR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Cipher Mining Inc — how do they compare? BioNTech SE - ADR trades at $92.94 (market cap $23.31B), while Cipher Mining Inc trades at $17.87 (market cap $7.14B). The key difference: BioNTech SE - ADR is far larger — about 3.3× Cipher Mining Inc's market cap, and Cipher Mining Inc is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | CIFR | |
|---|---|---|
Market Cap | $23.31B | $7.14B |
Sector | Health | Basic Materials |
52-Week High | $119.34 | $29.18 |
52-Week Low | $83.89 | $4.72 |
Enterprise Value | $6.60B | $11.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.72, down 0.09% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 revenue of €106 million, missing expectations due to weak COVID-19 vaccine demand, and lowered its 2026 sales outlook. Despite negative profitability metrics (net income margin -63.64%, ROE -9.3%), the balance sheet remains strong with $16.78 billion in cash. Analyst consensus is strongly bullish with 87.5% buy ratings and a $121 price target.
The outlook for BNTX hinges on its oncology pipeline development amid declining COVID revenue. Investment opportunity exists in the discounted valuation relative to cash reserves and potential pipeline catalysts. Key risks include execution on pipeline transitions, competitive pressure, and ongoing vaccine demand volatility. The stock trades near cash value, implying the market assigns minimal value to its advanced clinical programs.
CIFR trades at $17.87, up 9.43% in 24 hours, but remains in a bearish technical trend with significant fundamental challenges. The company reported a Q2 2026 loss of $0.65 per share, missing estimates, with revenue of $191 million and a net loss of $1.1 billion. Despite negative profitability metrics, analyst consensus is unanimously bullish with a $31.78 price target, citing progress in transitioning from Bitcoin mining to AI data center operations.
The outlook hinges on successful execution of its AI infrastructure pivot, but high valuation ratios and persistent losses pose substantial risks. Near-term support lies at $16, while resistance is at $18. Investor sentiment is divided between optimism over AI contracts and concerns over cash burn and mining dependency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Cipher Mining Inc
Cipher Mining is an industrial-scale technology company focused on Bitcoin mining infrastructure. It develops and operates data centers in the US designed to strengthen the Bitcoin network and support decentralized finance.
Read more on CIFR →
